Following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial evaluating aficamten, a next-in-class cardiac myosin inhibitor, in obstructive hypertrophic cardiomyopathy (HCM), ...

Following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial evaluating aficamten, a next-in-class cardiac myosin inhibitor, in obstructive hypertrophic cardiomyopathy (HCM), ...

Advancement of Fast Skeletal Muscle Troponin Activator Expands Pipeline of Muscle-Directed Drug Candidates SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Na ...

The Protein Sequencing Company™, today announced a newly released preprint publication on BioRxiv, from Dr. Gloria Sheynkman at the University of Virginia School of Medicine. In the publication, ...

A new report from cultivated meat co SuperMeat offers proof that with the right tech there is a "commercially viable path to ...

Farrant, JP, Schmitt, M, Reid, AB, Garratt, CJ, Newman, WG, Malhotra, A, Beynon, R, Mahmod, M, Raman, B, Cooper, RM, Dawson, D, Green, T, Prasad, SK, Singh, A, Dodd, S, Watkins, H, Neubauer, S and ...

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported a ...